6505--Intent to Sole Source | Xofigo RA-223 | Brand Name Only 5 YR-Indefinite Delivery/Indefinite Quantity (IDIQ) Multiple Stations (646, 642, 595)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Department of Veterans Affairs (VA), Network Contracting Office 4 (NCO4), intends to sole source a Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for Ra-223 Xofigo Radiopharmaceuticals for the Lebanon, Philadelphia, and VA Pittsburgh Healthcare Systems. The intended sole source is Cardinal Health, 414, LLC, under the authority of FAR 6.103-11. This notice seeks capability statements from other interested vendors by March 9, 2026, 10:00 AM EST.
Scope of Work
The contractor will provide timely delivery of brand-name Xofigo (Radium 223 dichloride) and continuous inventory management services for the Nuclear Medicine programs at the three VA Medical Centers. Key requirements include:
- Supplying Xofigo from non-High Enriched Uranium (non-HEU) sources (preferred).
- Holding current Nuclear Regulatory Commission (NRC) and FDA licenses.
- Providing barcode-labeled inserts compatible with Nuclear Medicine Information Systems (NMIS).
- Performing all required quality control procedures.
- Managing disposal of used/unused items and accepting returns under specified conditions.
- Adhering to HIPAA regulations and providing miscellaneous supplies/services (e.g., OSHA monitoring, calibration).
- The distributor must be located within the Philadelphia, Pittsburgh, and Lebanon-district area due to the radiopharmaceutical's 68-minute half-life.
Contract Details
- Contract Type: Fixed-price, Indefinite Delivery/Indefinite Quantity (IDIQ).
- Period of Performance: Five years, estimated from April 1, 2026, through March 31, 2029.
- NAICS Code: 325412 (Pharmaceutical and Medicine Manufacturing).
- SBA Standard: 1300.
- Estimated Annual Quantities: Lebanon (1500 uCi), Philadelphia (1000 uCi), Pittsburgh (1,900 uCi).
Submission & Evaluation
This is an Intent to Sole Source under FAR 6.103-11, not a request for quotations. Interested vendors capable of meeting the requirement must submit a one-page capability statement via email to christa.stine@va.gov. The statement should include Company Name, UEI SAM Number, Socioeconomic Category, and a brief description of capability. Responses will be evaluated, but the government reserves the right to proceed with the sole source negotiation with Cardinal Health if no suitable competitive responses are received.
Deadlines
- Capability Statement Due: March 9, 2026, 10:00 AM EST.
- Published Date: March 4, 2026.
Contact Information
- Contract Specialist: Christa Stine (christa.stine@va.gov, 570-824-3521).